UrologySchool.com

Guidelines: Difference between revisions

← Older edit
VisualWikitext
No edit summary
 
(35 intermediate revisions by the same user not shown)
Line 5: Line 5:
==== Prostate ====
==== Prostate ====


* [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]
Line 14: Line 15:
==== Bladder ====
==== Bladder ====


* [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2020)|Muscle-invasive Bladder Cancer (2020)]]
* '''<span style="color:#008000">NEW!</span>''' [[Microscopic Hematuria (2025)]]
* '''<span style="color:#008000">NEW!</span>''' [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2024 AUA)|Non-muscle Invasive Bladder Cancer (2024)]]
* [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]]
*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]]
*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]]
*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]]
*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]]
*[[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2020)|Muscle-invasive Bladder Cancer (2020)]]
* [[Muscle-invasive Bladder Cancer (2017)]]
* [[Muscle-invasive Bladder Cancer (2017)]]
* [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]]
* [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]]
Line 26: Line 30:
==== Testicular ====
==== Testicular ====


* (2019) Included in [https://test.urologyschool.com/index.php/Germ_Cell_Tumours Testicular Tumours Chapter Notes]
* (2019) Included in [[Germ Cell Tumours|Testicular Tumours Chapter Notes]]


==== Upper Tract Urothelial Carcinoma ====
==== Upper Tract Urothelial Carcinoma ====
Line 35: Line 39:
==== Andrology ====
==== Andrology ====


* '''<span style="color:#008000">NEW!</span>''' [[Priapism|Priapism (2021)]]
* [[Testosterone Deficiency (2024)]]
*[[Testosterone Deficiency (2018)]]
* [[Priapism|Priapism (2021)]]
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]]
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]]
* [[Peyronie's Disease (2015)]]
* [[Peyronie's Disease (2015)]]
Line 42: Line 46:
==== Functional ====
==== Functional ====


* '''<span style="color:#008000">NEW!</span>''' [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]
* '''<span style="color:#008000">NEW!</span>''' [[Incontinence after Prostate Therapy (2024)]]
* [[AUA: Overactive Bladder (2019)|Overactive Bladder (2024)]]
* [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]
Line 50: Line 55:
==== Infertility ====
==== Infertility ====


* '''<span style="color:#008000">NEW!</span>''' AUA/ASRM Infertility (2020) included in Chapter Notes of  
* AUA/ASRM Infertility (2020) included in Chapter Notes of  
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]]
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]]
** [[Infertility: Management|Management of Infertility]]
** [[Infertility: Management|Management of Infertility]]
Line 59: Line 64:


==== Pediatrics ====
==== Pediatrics ====
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]]
*[[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]]
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]]
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]]


Line 69: Line 74:
==== Other ====
==== Other ====


* '''<span style="color:#008000">NEW!</span>''' [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]
* [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]
*[[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]]
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]]
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]
Line 76: Line 82:
==== Contribute ====
==== Contribute ====


* [https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer Salvage Therapy for Prostate Cancer (2024)]
* Incontinence after Prostate Therapy (2024 Amendment)
*[https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline Muscle Invasive Bladder Cancer (2024)]
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024)
*Management of LUTS attributed to BPH (2023 Amendment)
*Interstitial Cystitis/Bladder Pain Syndrome (2022)
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]
*Disorders of ejaculation (2020)
*Disorders of ejaculation (2020)
Line 107: Line 112:
==== Kidney ====
==== Kidney ====


* '''<span style="color:#008000">NEW!</span>''' [[CUA: Cystic Renal Lesions (2023)|Cystic Renal Lesions (2023)]]
* [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]]
* [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]]
* [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]]
* [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]]
Line 168: Line 174:
* Pheochromocytoma surveillance (2019)
* Pheochromocytoma surveillance (2019)
* Pediatric hemorrhagic cystitis (2019)
* Pediatric hemorrhagic cystitis (2019)
== Other Guidelines ==
=== '''<span style="color:#008000">NEW!</span>''' [[EAU & ASCO: Penile Cancer 2023|Penile Cancer (EAU/ASCO 2023)]] ===
Retrieved from "https://urologyschool.com/wikiuro/index.php/Guidelines"